Avacta appoints Shaun Chilton as Non-executive Director
Appointment brings additional, significant commercial and corporate development experience to the Board
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that Shaun Chilton has today joined the Board as a Non-executive Director.
Shaun Chilton was most recently Chief Executive Officer (“CEO”) of the formerly London-listed Clinigen Group plc (“Clinigen”), a global pharmaceutical and pharmaceutical services platform business, which he led through a significant growth journey. During his tenure, the company expanded through both an organic and a buy-and-build strategy which included successfully completing several transformational acquisitions. The Company was eventually sold to Triton Partners for a total consideration of c.£1.3 billion in April 2022.
Alongside his role as the CEO of Clinigen, Shaun was Non-Executive Chairman of C7Health, a disruptive, venture capital-backed medical technology and services business which executed an acquisitive growth journey before successfully being acquired by a strategic buyer in 2022.
Shaun has held a number of senior and executive commercial positions over more than 30 years in companies in pharmaceutical and pharmaceutical services industries. These include at Pfizer, Sanofi, Wolters Kluwer Health and KnowledgePoint360 Group (now part of UDG Healthcare).
Dr Eliot Forster, Chairman of the Board of Avacta Group plc commented:
“Along with my fellow Directors I am delighted to welcome Shaun to the Board of Avacta Group. He brings a wide range of highly relevant commercial experiences from successful healthcare businesses with similar ambitions for growth that we have in Avacta. I know Shaun will positively impact our shared thinking and I’m excited to have him join the company.”
Dr Alastair Smith, Chief Executive of Avacta Group plc commented:
“I am delighted that Shaun has joined the Board of Avacta Group. He brings deep and extensive commercial experience to further strengthen the senior leadership of the Group as it executes its strategy across two divisions to build a major global healthcare business working to improve people’s health and well-being through innovative oncology drugs and powerful diagnostics.”
Shaun Chilton, Non-Executive Director of Avacta Group, commented:
“Avacta Group is building a high value, global business that is seeking to significantly improve people’s health and well-being. I am excited to leverage my own broad experience of growing healthcare businesses and working with the other members of the Board to help guide Avacta to meet its very significant potential.”
Regulatory disclosure – The following disclosures are made in accordance with Schedule 2(g) of the AIM Rules for Companies:
Shaun Edward Chilton, aged 55, holds no ordinary shares or options in the Company. Shaun Chilton’s current and previous directorships are as follows:
| Current Directorships | Previous Directorships (last 5 years) |
| Bellbrook Consulting Ltd.
Mustang Topco Ltd., (trading as MAP Patient Access) Mustang Midco Ltd., (trading as MAP Patient Access) Mustang Bidco Ltd. (trading as MAP Patient Access)
|
C7 Health Ltd.Clinigen Clinical Trials Ltd.
Clinigen CTS Ltd. Clinigen International Holdings Ltd. Clinigen Pharma Ltd. Clinigen Holdings Ltd. Clinigen GAP Ltd. Clinigen SP Ltd. Clinigen Healthcare Ltd. Clinigen Ltd. Clinigen Consulting Ltd. IDIS Pharma Ltd. IDIS Group Holdings Ltd. IDIS Group Ltd. IDIS MA Ltd. IDIS Ltd. IDIS GA Ltd. Keats Healthcare Ltd. |
Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.